BPC-157

No, BPC-157 is not approved by the FDA or any regulatory agency for human use. It is classified as an unapproved drug. The FDA has issued warnings about BPC-157 being found in compounded products and dietary supplements. Only one Phase 1 clinical trial has been registered, and no Phase 2 or 3 trials have been completed.

Preclinical research (animal studies) has shown BPC-157 may accelerate healing of tendons, ligaments, muscles, and bones; protect the gastrointestinal tract from ulcers and inflammation; have neuroprotective effects; and promote blood vessel formation (angiogenesis). However, these findings have not been confirmed in large-scale human clinical trials.

In research settings, BPC-157 has been administered via multiple routes: subcutaneous injection, intramuscular injection, intravenous infusion, intraperitoneal injection (in animals), and orally. The compound is remarkably stable in gastric juice for over 24 hours, supporting oral bioavailability. Common research doses range from 10 ng/kg to 10 μg/kg in animal studies.

While preclinical studies show no significant toxicity, human safety data is very limited. Key concerns include: lack of FDA approval, unknown long-term effects, theoretical risk of promoting tumor growth due to angiogenic properties, quality control issues with unregulated products, and banned status by WADA since 2022. The compound is not recommended for human use outside of clinical research settings.

Lyophilized (powder) form should be stored at -20°C for long-term stability. Once reconstituted, it should be kept at 2-8°C and used within approximately 30 days. The compound demonstrates remarkable stability and can withstand room temperature for short periods. It resists hydrolysis, enzymatic degradation, and even gastric acid.